Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.

Blood
Michelle A FanaleAnas Younes

Abstract

Nodular lymphocyte Hodgkin lymphoma (NLPHL) is a rare disease for which the optimal therapy is unknown. We hypothesized that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) could decrease rates of relapse and transformation. We retrospectively reviewed patients with NLPHL diagnosed between 1995 and 2015 confirmed by central pathologic review. Fifty-nine had sufficient treatment and follow-up data for analysis. We described progression-free survival (PFS), overall survival (OS), and histologic transformation according to treatment strategy and explored prognostic factors for PFS and OS. The median age at diagnosis was 41 years; 75% were male, and 61% had a typical growth pattern. Twenty-seven patients were treated with R-CHOP with an overall response rate of 100% (complete responses 89%). The median follow-up was 6.7 years, and the estimated 5- and 10-year PFS rates for patients treated with R-CHOP were 88.5% (95% confidence interval [CI], 68.4% to 96.1%) and 59.3 (95% CI, 25.3% to 89.1%), respectively. Excluding patients with histologic transformation at diagnosis, the 5-year cumulative incidence of histologic transformation was 2% (95% CI, 87% to 100%). No patient treated with R-CHOP experien...Continue Reading

References

Jun 1, 1996·Histopathology·P G Isaacson
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Nov 6, 2002·The Cancer Journal·Pamela J SchlembachJames D Cox
Feb 15, 2003·Blood·Bradley C EkstrandSandra J Horning
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George P Canellos, Peter Mauch
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald C ChenPeter M Mauch
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mubarak Al-MansourKerry J Savage
Nov 19, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ananth ShankarJudith Landman-Parker
Nov 12, 2013·Blood·Ranjana H Advani, Richard T Hoppe
Sep 4, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D A EichenauerUNKNOWN ESMO Guidelines Working Group
Aug 5, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dennis A EichenauerAndreas Engert
Sep 13, 2016·CA: a Cancer Journal for Clinicians·Lauren R TerasChristopher R Flowers

❮ Previous
Next ❯

Citations

Nov 9, 2018·British Journal of Haematology·Hao-Wei WangElaine S Jaffe
Feb 17, 2019·Blood·Sven BorchmannDavid J Straus
Oct 19, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dennis A EichenauerAndreas Engert
Jan 11, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy L Bartlett
Jul 29, 2017·Blood·Dennis A Eichenauer, Andreas Engert
Nov 30, 2018·British Journal of Haematology·Michael A SpinnerRanjana H Advani
Aug 1, 2019·Cancers·Theodoros P VassilakopoulosKostas Konstantopoulos
Feb 8, 2019·British Journal of Haematology·Monika L Metzger, Christine Mauz-Körholz
Jul 25, 2020·Nature Reviews. Disease Primers·Joseph M ConnorsNancy L Bartlett
Nov 12, 2017·Paediatric Drugs·Christine Mauz-KörholzDieter Körholz
Dec 2, 2017·CA: a Cancer Journal for Clinicians·Satish Shanbhag, Richard F Ambinder
Oct 13, 2020·The Journal of Pathology·Sibrandes Poppema
Sep 3, 2020·Blood·Dennis A Eichenauer, Andreas Engert
Mar 19, 2021·Pediatric Hematology and Oncology·Tomasz KlekawkaSzymon Skoczen
Sep 30, 2020·Archives of Pathology & Laboratory Medicine·Joshua R MenkeDita A Gratzinger
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D A EichenauerUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Jul 6, 2021·Current Opinion in Oncology·Dennis A Eichenauer, Andreas Engert

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Dennis A EichenauerAndreas Engert
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Mubarak Al-MansourKerry J Savage
Nihon rinsho. Japanese journal of clinical medicine
Hirokazu Nagai
© 2022 Meta ULC. All rights reserved